The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; Amgen; Amgen; Amgen; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Novartis; Novartis; Novartis; Novartis; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Research Funding - GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis; Novartis; Novartis; Novartis; Roche; Roche; Roche; Roche
 
Consulting or Advisory Role - Adaptimmune; Adaptimmune; Adaptimmune; Adaptimmune; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Deciphera; Deciphera; Deciphera; Deciphera; Eisai; Eisai; Eisai; Eisai; Epizyme; Epizyme; Epizyme; Epizyme; Immodulon Therapeutics; Immodulon Therapeutics; Immodulon Therapeutics; Immodulon Therapeutics; Immune Design; Immune Design; Immune Design; Immune Design; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Morphotek; Morphotek; Morphotek; Morphotek; PharmaMar; PharmaMar; PharmaMar; PharmaMar; TRACON Pharma; TRACON Pharma; TRACON Pharma; TRACON Pharma
Research Funding - GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - PharmaMar; PharmaMar; PharmaMar; PharmaMar
Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST).
 
Michael C. Heinrich
Stock and Other Ownership Interests - MolecularMD; MolecularMD; MolecularMD; MolecularMD
Honoraria - Novartis; Novartis; Novartis; Novartis
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Deciphera; Deciphera; Deciphera; Deciphera; MolecularMD; MolecularMD; MolecularMD; MolecularMD; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer
Research Funding - Blueprint Medicines (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Deciphera (Inst); Deciphera (Inst); Deciphera (Inst); Deciphera (Inst)
Patents, Royalties, Other Intellectual Property - Patent on treatment of GIST-licensed to Novartis (Inst); Patent on treatment of GIST-licensed to Novartis (Inst); Patent on treatment of GIST-licensed to Novartis (Inst); Patent on treatment of GIST-licensed to Novartis (Inst)
Expert Testimony - Novartis; Novartis; Novartis; Novartis
 
Robin L. Jones
No Relationships to Disclose
 
Margaret von Mehren
Honoraria - Pfizer; Pfizer; Pfizer; Pfizer
Consulting or Advisory Role - deciphera; deciphera; deciphera; deciphera
Research Funding - Arog (Inst); Arog (Inst); Arog (Inst); Arog (Inst); ArQule; ArQule; ArQule; ArQule; Blueprint Medicines (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Deciphera (Inst); Deciphera (Inst); Deciphera (Inst); Deciphera (Inst); Genmab (Inst); Genmab (Inst); Genmab (Inst); Genmab (Inst); Gradalis (Inst); Gradalis (Inst); Gradalis (Inst); Gradalis (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Springworks Therapeutics (Inst); Springworks Therapeutics (Inst); Springworks Therapeutics (Inst); Springworks Therapeutics (Inst)
Travel, Accommodations, Expenses - Deciphera; Deciphera; Deciphera; Deciphera
Other Relationship - NCCN; NCCN; NCCN; NCCN
 
Sebastian Bauer
Honoraria - Bayer; Bayer; Bayer; Bayer; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Pharmamar; Pharmamar; Pharmamar; Pharmamar
Consulting or Advisory Role - ADC Therapeutics; ADC Therapeutics; ADC Therapeutics; ADC Therapeutics; Bayer; Bayer; Bayer; Bayer; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Deciphera; Deciphera; Deciphera; Deciphera; Exelixis; Exelixis; Exelixis; Exelixis; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Lilly; Lilly; Lilly; Lilly; Nanobiotix; Nanobiotix; Nanobiotix; Nanobiotix
Research Funding - Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Novartis; Novartis; Novartis; Novartis
Travel, Accommodations, Expenses - Pharmamar; Pharmamar; Pharmamar; Pharmamar
 
Yoon-Koo Kang
No Relationships to Disclose
 
Patrick Schoffski
Consulting or Advisory Role - Adaptimmune (Inst); Adaptimmune (Inst); Adaptimmune (Inst); Adaptimmune (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Deciphera; Deciphera; Deciphera; Deciphera; Deciphera (Inst); Deciphera (Inst); Deciphera (Inst); Deciphera (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Ellipses Pharma (Inst); Ellipses Pharma (Inst); Ellipses Pharma (Inst); Ellipses Pharma (Inst); Exelixis; Exelixis; Exelixis; Exelixis; Genmab (Inst); Genmab (Inst); Genmab (Inst); Genmab (Inst); Intellisphere (Inst); Intellisphere (Inst); Intellisphere (Inst); Intellisphere (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Loxo (Inst); Loxo (Inst); Loxo (Inst); Loxo (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); SERVIER (Inst); SERVIER (Inst); SERVIER (Inst); SERVIER (Inst); Transgene (Inst); Transgene (Inst); Transgene (Inst); Transgene (Inst)
Research Funding - Blueprint Medicines (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); CoBioRes NV (Inst); CoBioRes NV (Inst); CoBioRes NV (Inst); CoBioRes NV (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); G1 Therapeutics (Inst); G1 Therapeutics (Inst); G1 Therapeutics (Inst); G1 Therapeutics (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); PharmaMar (Inst); PharmaMar (Inst); PharmaMar (Inst); PharmaMar (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst)
 
Ferry Eskens
Consulting or Advisory Role - Eisai; Eisai; Eisai; Eisai; Ipsen; Ipsen; Ipsen; Ipsen; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Roche; Roche; Roche; Roche
Travel, Accommodations, Expenses - Pfizer; Pfizer; Pfizer; Pfizer
 
Olivier Mir
Stock and Other Ownership Interests - Transgene; Transgene; Transgene; Transgene
Honoraria - Roche; Roche; Roche; Roche
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Lilly; Lilly; Lilly; Lilly; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Roche; SERVIER; SERVIER; SERVIER; SERVIER; Vifor Pharma; Vifor Pharma; Vifor Pharma; Vifor Pharma
Speakers' Bureau - Lilly; Lilly; Lilly; Lilly; Roche; Roche; Roche; Roche
Travel, Accommodations, Expenses - Pfizer; Pfizer; Pfizer; Pfizer; PharmaMar; PharmaMar; PharmaMar; PharmaMar; Roche; Roche; Roche; Roche
 
Philippe Cassier
No Relationships to Disclose
 
Cesar Serrano
Honoraria - Bayer; Bayer; Bayer; Bayer
Consulting or Advisory Role - Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Deciphera; Deciphera; Deciphera; Deciphera
Research Funding - Bayer; Bayer; Bayer; Bayer; Deciphera; Deciphera; Deciphera; Deciphera; Pfizer; Pfizer; Pfizer; Pfizer
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer; Lilly; Lilly; Lilly; Lilly; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; PharmaMar; PharmaMar; PharmaMar; PharmaMar
 
William D. Tap
Leadership - Atropos; Atropos; Atropos; Atropos; Certis Oncology Solutions; Certis Oncology Solutions; Certis Oncology Solutions; Certis Oncology Solutions
Stock and Other Ownership Interests - Atropos; Atropos; Atropos; Atropos; Certis Oncology Solutions; Certis Oncology Solutions; Certis Oncology Solutions; Certis Oncology Solutions
Consulting or Advisory Role - Agios; Agios; Agios; Agios; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Eisai; Eisai; Eisai; Eisai; EMD Serono; EMD Serono; EMD Serono; EMD Serono; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Immune Design; Immune Design; Immune Design; Immune Design; Janssen; Janssen; Janssen; Janssen; Lilly; Lilly; Lilly; Lilly; Loxo; Loxo; Loxo; Loxo; Nanocell Therapy; Nanocell Therapy; Nanocell Therapy; Nanocell Therapy; Novartis; Novartis; Novartis; Novartis
Research Funding - BioAtla; BioAtla; BioAtla; BioAtla; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Deciphera; Deciphera; Deciphera; Deciphera; Immune Design; Immune Design; Immune Design; Immune Design; Lilly; Lilly; Lilly; Lilly; Novartis; Novartis; Novartis; Novartis; Plexxikon; Plexxikon; Plexxikon; Plexxikon; TRACON Pharma; TRACON Pharma; TRACON Pharma; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Companion Diagnostic for CDK4 inhibitors - 14/854,329; Companion Diagnostic for CDK4 inhibitors - 14/854,329; Companion Diagnostic for CDK4 inhibitors - 14/854,329
 
Jonathan C. Trent
Honoraria - GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline
Consulting or Advisory Role - Janssen; Janssen; Janssen; Janssen; Lilly; Lilly; Lilly; Lilly; Novartis; Novartis; Novartis; Novartis
 
Piotr Rutkowski
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; Lilly; Lilly; Lilly; MSD; MSD; MSD; MSD; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Roche
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD; MSD; MSD; MSD; Novartis; Novartis; Novartis; Novartis; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre
Speakers' Bureau - Lilly; Lilly; Lilly; Lilly; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Orphan Europe; Orphan Europe; Orphan Europe; Orphan Europe; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre
 
Shreyaskumar Patel
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Epizyme; Epizyme; Epizyme; Epizyme; Immune Design; Immune Design; Immune Design; Immune Design; Janssen; Janssen; Janssen; Janssen; Lilly; Lilly; Lilly; Lilly; MaxiVax ; MaxiVax ; MaxiVax ; MaxiVax ; Novartis; Novartis; Novartis; Novartis
Research Funding - Blueprint Medicines (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst)
 
Sant P. Chawla
Honoraria - Amgen; Amgen; Amgen; Amgen; CytRx Corporation; CytRx Corporation; CytRx Corporation; CytRx Corporation; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Ignyta; Ignyta; Ignyta; Ignyta; Immune Design; Immune Design; Immune Design; Immune Design; Janssen; Janssen; Janssen; Janssen; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Roche; Roche; Roche; Roche; SARC: Sarcoma Alliance for Research though Collaboration; SARC: Sarcoma Alliance for Research though Collaboration; SARC: Sarcoma Alliance for Research though Collaboration; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; Threshold Pharmaceuticals; Threshold Pharmaceuticals; Threshold Pharmaceuticals; TRACON Pharma; TRACON Pharma; TRACON Pharma; TRACON Pharma
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; CytRx Corporation; CytRx Corporation; CytRx Corporation; CytRx Corporation; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Ignyta; Ignyta; Ignyta; Ignyta; Immune Design; Immune Design; Immune Design; Immune Design; Janssen; Janssen; Janssen; Janssen; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Roche; Roche; Roche; Roche; SARC: Sarcoma Alliance for Research though Collaboration; SARC: Sarcoma Alliance for Research though Collaboration; SARC: Sarcoma Alliance for Research though Collaboration; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; Threshold Pharmaceuticals; Threshold Pharmaceuticals; Threshold Pharmaceuticals; TRACON Pharma; TRACON Pharma; TRACON Pharma; TRACON Pharma
Speakers' Bureau - Amgen; Amgen; Amgen; Amgen; CytRx Corporation; CytRx Corporation; CytRx Corporation; CytRx Corporation; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Ignyta; Ignyta; Ignyta; Ignyta; Immune Design; Immune Design; Immune Design; Immune Design; Janssen; Janssen; Janssen; Janssen; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Roche; Roche; Roche; Roche; SARC: Sarcoma Alliance for Research though Collaboration; SARC: Sarcoma Alliance for Research though Collaboration; SARC: Sarcoma Alliance for Research though Collaboration; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; Threshold Pharmaceuticals; Threshold Pharmaceuticals; Threshold Pharmaceuticals; TRACON Pharma; TRACON Pharma; TRACON Pharma; TRACON Pharma
Research Funding - Amgen; Amgen; Amgen; Amgen; CytRx Corporation; CytRx Corporation; CytRx Corporation; CytRx Corporation; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Ignyta; Ignyta; Ignyta; Ignyta; Immune Design; Immune Design; Immune Design; Immune Design; Janssen; Janssen; Janssen; Janssen; Janssen; Janssen; Janssen; Janssen; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Roche; Roche; Roche; Roche; SARC: Sarcoma Alliance for Research though Collaboration; SARC: Sarcoma Alliance for Research though Collaboration; SARC: Sarcoma Alliance for Research though Collaboration; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; Threshold Pharmaceuticals; Threshold Pharmaceuticals; Threshold Pharmaceuticals; TRACON Pharma; TRACON Pharma; TRACON Pharma; TRACON Pharma
 
Eyal Meiri
Employment - Cancer Treament Centers of America; Cancer Treament Centers of America; Cancer Treament Centers of America; Cancer Treament Centers of America; Cancer Treament Centers of America (I); Cancer Treament Centers of America (I); Cancer Treament Centers of America (I); Cancer Treament Centers of America (I)
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen
 
Teresa Zhou
Employment - Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines
 
Maria Roche
Employment - Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines
 
Suzanne George
Stock and Other Ownership Interests - Abbott Laboratories; Abbott Laboratories; Abbott Laboratories; Abbott Laboratories; Abbvie (I); Abbvie (I); Abbvie (I); Abbvie (I); Allergan (I); Allergan (I); Allergan (I); Allergan (I)
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Deciphera; Deciphera; Deciphera; Deciphera; Lilly; Lilly; Lilly; Lilly; MORE Health; MORE Health; MORE Health; MORE Health; Research to Practice; Research to Practice; Research to Practice; Research to Practice; UpToDate; UpToDate; UpToDate; UpToDate
Research Funding - ARIAD (Inst); ARIAD (Inst); ARIAD (Inst); ARIAD (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Deciphera (Inst); Deciphera (Inst); Deciphera (Inst); Deciphera (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst)
Expert Testimony - Bayer; Bayer; Bayer; Bayer